Methods and compositions for attenuating antibody-mediated xenograft rejection in human recipients
AssigneesAlberta Research Council, Integris Baptist Medical Center, Inc.
InventorsA. Heather Good, David K.C. Cooper, Andrew J. Malcolm
Life of this patent
Estimating the term…
Abstract
Antibody-mediated xenograft rejection is attenuated by (1) removing preformed antibodies to various identified carbohydrate xenoantigens from the recipient's circulation prior to transplantation by extracorporeal perfusion of the recipient's blood over a biocompatible solid support to which the xenoantigens are bound and/or (2) parenterally administering a xenoantibody-inhibiting amount of an identified xenoantigen to the recipient shortly before graft revascularization and thereafter.
Claims8
A method for attenuating antibody-mediated xenograft rejection in a human recipient of a xenograft comprising:
- (a) selecting at least one carbohydrate antigen of the glycoside structure of formula 2 of FIG. 1A where X is —O— and Y is —A—Z where A is alkylene of 2 to 10 carbon atoms and Z is selected from the group consisting of —C(O)R2, —C(O)NH2, and —C(O)NHR2 and R2 is hydrogen or alkyl of from 1 to 4 carbon atoms which reacts with preformed antibodies to at least one carbohydrate antigen of said xenograft that is involved in the rejection;
- (b) attaching said selected antigen(s) to a biocompatible solid support through a compatible linker arm;
- (c) withdrawing antibody-containing body fluid from the recipient;
- (d) removing said preformed antibodies to at least one carbohydrate antigen of said xenograft that is involved in the rejection from the withdrawn body fluid by extracorporeal perfusion of the body fluid over the biocompatible solid support of step (b) wherein said preformed antibodies in said blood or plasma are removed in order to render the composition useful for infusing into the human recipient of a xenograft to attenuate rejection of said xenograft;
- and
- (e) reintroducing the perfused body fluid into the recipient.
A method for attenuating antibody-mediated xenograft rejection in a human recipient of a xenograft comprising:
- (a) selecting at least one carbohydrate antigen of the glycoside structure of formula 4 of FIG. 1A where X is —O— and Y is —A—Z where A is alkylene of 2 to 10 carbon atoms and Z is selected from the group consisting of —C(O)R2, —C(O)NH2, and —C(O)NHR2 and R2 is hydrogen or alkyl of from 1 to 4 carbon atoms which reacts with preformed antibodies to at least one carbohydrate antigen of said xenograft that is involved in the rejection;
- (b) attaching said selected antigen(s) to a biocompatible solid support through a compatible linker arm;
- (c) withdrawing antibody-containing body fluid from the recipient;
- (d) removing said preformed antibodies to at least one carbohydrate antigen of said xenograft that is involved in the rejection from the withdrawn body fluid by extracorporeal perfusion of the body fluid over the biocompatible solid support of step (b) wherein said preformed antibodies in said blood or plasma are removed in order to render the composition useful for infusing into the human recipient of a xenograft to attenuate rejection of said xenograft;
- and
- (e) reintroducing the perfused body fluid into the recipient.
Dependencies are inferred from the claim text.